Sugi Predict

Sugi Predict / Targets / MAP3K12

MAP3K12

Mitogen-activated protein kinase kinase kinase 12 · Q12852 · MAP3K12 on Sugi Atlas →

23,978 patent compounds predicted against MAP3K12, 8,690 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3432395 SCHEMBL3432395 0.52 18/20
SCHEMBL69487 SCHEMBL69487 0.42 18/20
SCHEMBL3432392 SCHEMBL3432392 0.52 16/20
SCHEMBL626620 SCHEMBL626620 0.52 15/20
SCHEMBL3512871 SCHEMBL3512871 0.44 14/20
SCHEMBL2338512 SCHEMBL2338512 0.41 14/20
SCHEMBL3230699 SCHEMBL3230699 0.53 13/20
SCHEMBL3512134 SCHEMBL3512134 0.36 11/20
SCHEMBL3515935 SCHEMBL3515935 0.35 11/20
SCHEMBL628521 SCHEMBL628521 0.57 10/20
SCHEMBL901925 SCHEMBL901925 0.54 10/20
SCHEMBL1108634 SCHEMBL1108634 0.44 10/20
SCHEMBL1431136 SCHEMBL1431136 0.42 10/20
SCHEMBL625281 SCHEMBL625281 0.40 10/20
SCHEMBL626700 SCHEMBL626700 0.39 10/20
SCHEMBL626579 SCHEMBL626579 0.38 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL2722961) 0.52 9/20
SCHEMBL901953 SCHEMBL901953 0.49 9/20
SCHEMBL3514558 SCHEMBL3514558 0.45 9/20
SCHEMBL532091 SCHEMBL532091 0.43 9/20

Clinical trials — most relevant to MAP3K12 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE2COMPLETED
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies PHASE1/PHASE2RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy nanUNKNOWN
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP3K12 binder may also engage these)

ProteinNameSimilarity
Q60700 — 1.000 Q60700 →
A7MBB4 — 1.000 A7MBB4 →
Q80UE6 — 0.999 Q80UE6 →
Q63796 — 0.998 Q63796 →
Q3U1V8 — 0.998 Q3U1V8 →
Q96J92 — 0.998 Q96J92 →
D3ZG83 — 0.997 D3ZG83 →
TESK2 Dual specificity testis-specific protein kinase 2 0.997 landscape →
Q8BLR5 — 0.997 Q8BLR5 →
Q61501 — 0.997 Q61501 →
Q6PCN3 — 0.996 Q6PCN3 →
Q7TPK6 — 0.996 Q7TPK6 →
Q8VHQ2 — 0.996 Q8VHQ2 →
Q8VDG6 — 0.996 Q8VDG6 →
Q60610 — 0.996 Q60610 →
Q9H4Z2 — 0.995 Q9H4Z2 →
LMTK3 Serine/threonine-protein kinase LMTK3 0.995 landscape →
MAST4 Microtubule-associated serine/threonine-protein kinase 4 0.995 landscape →
Q80YF9 — 0.995 Q80YF9 →
P53814 — 0.994 P53814 →
Q8WYL5 — 0.994 Q8WYL5 →
Q80UW3 — 0.994 Q80UW3 →
Q7Z6I6 — 0.994 Q7Z6I6 →
E9Q9W7 — 0.994 E9Q9W7 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.994 landscape →
Q6AY88 — 0.994 Q6AY88 →
Q7TN02 — 0.994 Q7TN02 →
Q7TNN8 — 0.994 Q7TNN8 →
E7FBS9 — 0.994 E7FBS9 →
Q04888 — 0.994 Q04888 →